Theragenomics Associates offers integrated consulting services in areas where theragenomics-based knowledge and data play an increasingly important role in either personal or corporate life. Depending on the needs of our customers (see below for groups of customers), we deliver

• expert commentaries on gene test results for informed patients;
• drug safety risk/benefit evaluations for single patients or subgroups of patients;
• pharmacoeconomic stratifications of large patient groups based on genetic outfit;
• displays and illustrations generated from within ThassoBase^TM customized towards your needs;
• courses and trainig sessions on the impact of theragenomics on your business;
• analyses and reviews of large amounts of preclinical, clinical, and postmarketing data;
• contributions to investigators brochures, product monographs, and regulatory documents;
• study and expert reports / special assessment reports;
• environmental impact (EIA) and exotoxicological risk (ERA) assessments;
• customized database entries such as generation of IUCLID-5 import/export files.

Informed Patients and Individuals

As an informed patient, you have received from your physician or your laboratory the results of a pharmacogenetic test, or you have dared to obtain a whole genome analysis through internet-based services. You are concerned or overwhelmed by the test results for biomarkers such as CYP2D6, CYP2C9, CYP2C19, UGTA1, TPMT, GST1, GSTM1, DIA4, SOD1, MPO, COMT, XRCC1, NQO1, SULT1A1, VKOR, NAT-2, FMO3, PON1, G6PD, EGFR, DPD, CCR5, LDL, Her-2/neu, PMT/RAR, C-KIT, HLA-B*1502, HLA-B*1302, and many others? May be you are a plaintiff in a toxic injury litigation and you would like to understand how such biomarkers may be used to differentiate among individuals with respect to individual susceptibility and predisposition to injury and personal health damage? You don’t understand the language and therefore the meaning of the result, and you feel left alone? Talk to us, we can help you to understand these results and also to alleviate your concerns.

Outside Professionals

Lawyers, Investors, Financial Analysts, Risk Analysts, Writers, they are all, knowingly or unknowingly, confronted with the influence theragenomics and consumer genomics has in their daily business decisions. Talk to us, we can help you to extract, understand, and apply the knowledge relevant for your business case. We can help you in prospective risk/benefit evaluations on the efficacy and safety of future pharmaceutical products based on valid biomarkers and genetic outfit based patient stratification.

Physicians & Health Care Professionals

You are overwhelmed by the amount and complexicity of the information that comes along with the results of pharmacogenetic tests you requested on behalf of your patients? Or a patient of yours confronts you with the results of a whole genome analysis? We can cempetently help and support you in the interpretation of these tests.

Health Care Providers & Insurance Companies

We help you to pharmacoeconomically stratify, based on valid biomarker and genetic outfit, groups of patients which exhibiti 1) high drug efficacy in combination with no adverse events; 2) high drug efficacy in combination with serious drug adverse events; 3) lack of drug efficacy in combination with no drug adverse events, and 4) lack of drug efficacy in combination with serious drug adverse events. Similarly, we help you to evaluate and stratify risk potentials for selected drugs in underwriting, claims, conflict resolution, and arbitration.

Regulatory Authorities /Pharmaceutical, Chemical, and Food Industires

Integration of pharmaco- and toxicogenomic data in knowledge bases and drug labels. Prospective drug candidate stratification based on exploratory and valid biomarkers and genetic outfit of single patients or groups of patients within the therapeutic target population. Assessment of risks of exposure of single individuals or groups of individuals with selected genetic backgrounds to environmental and occupational agents and pollutants, agro- and petrochemicals, and bulk chemicals. Assessment of risks of exposure of single individuals or groups of individuals to nutriceuticals such as dietary supplements and herbal extracts. Customized atabase entries such as IUCLID-5.